NEW YORK, April 4 – Cambridge Antibody Technology of Melbourn, UK, said Wednesday it had filed a request with the US Securities and Exchange Commission to list American Depositary Receipts on the Nasdaq.

Rowena Gardner, head of corporate communications at CAT, said the company, which trades on the London Stock Exchange, decided to list ADRs on the Nasdaq in order to better service investors.

“Forty percent of our investors are in the states,” Gardner said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.